Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease

Bone Marrow Transplantation

Volumn 45, Issue 5, 2010, Pages 919-924

  Pidala, J ^a,b   Kim, J ^a,b   Perkins, J ^a,b   Field, T ^a,b   Fernandez, H ^a,b   Perez, L ^a,b   Ayala, E ^a,b   Kharfan Dabaja, M ^a,b   Anasetti, C ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Acute graft vs host disease; Mycophenolate mofetil; Steroid refractory

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DENILEUKIN DIFTITOX; FLUDARABINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG TOLERABILITY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PUVA; REMISSION; SALVAGE THERAPY;

ACUTE DISEASE; ADULT; DRUG RESISTANCE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77952429682     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.252     Document Type: Article

References (39)

1. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-2759.
2. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8:387-394.
3. Copelan EA. Hematopoietic stem cell transplantation. NEJM 2006;354:1813-1826.
4. Antin JH, Ferrara JL. Cytokine dysregulation and acute graftversus-host disease. Blood 1992;80:2964-2968.
5. Chao NJ, Chen BJ. Prophylaxis and treatment of acute graftversus-host disease. Semin Hematol 2006;43:32-41.
6. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study com paring methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-2314.
7. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96:2062-2068.
8. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graftversus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk factors and outcome. Blood 1990;75:1024.
9. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76:1464-1472.
10. Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109:4119-4126.
11. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli F et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998;92:2288.
12. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R et al. Treatment of steroid-resistant acute graft vs host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001;27:1059-1064. (Pubitemid 32591189)
13. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graftversus-host disease. Biol Blood Marrow Transplant 2002;8:40-46.
14. Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD et al. Treatment of steroid-resistant graft-versushost disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995;15:891-894.
15. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002;99:2712-2719.
16. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:465-471.
17. Hervé P, Wijdenes J, Bergerat JP, Bordigoni P, Milpied N, Cahn JY et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of antiinterleukin-2 receptor monoclonal antibody (B-B10). Blood 1990;75:1017.
18. Wijdenes J, Beliard R, Muot S, Herve P, Peters A. A semipharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study. Dev Biol Stand 1990;71:103.
19. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994;84:1320.
20. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized antiinterleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83.
21. Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F et al. Daclizumab, an efficient treatment for steroidrefractory acute graft-versus-host disease. Br J Haematol 2006;135:382.
22. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy Jr PL et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graftversus-host disease: results of a randomized trial. Blood 2004;104:1559.
23. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABXCBL. Blood 2001;98:2052-2058.
24. Heslop HE, Benaim E, Brenner MK, Krance RA, Stricklin LM, Rochester RJ et al. Response of steroid-resistant graftversus-host disease to lymphoblast antibody CBL1. Lancet 1995;346:805-806.
25. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR et al. A phase II/III multi-center randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007;109:2657-2662.
26. Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 2000;12:582-587.
27. Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23:2661.
28. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:1224.
29. Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000;96:2426.
30. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002;6:296.
31. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD. Bone Marrow Transplant 1998;22:61-65.
32. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 2005;84:681-685.
33. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 2002;30:287-295.
34. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825.
35. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956. (Pubitemid 41754712)
36. Mori M, Muroi K, Matsuyama T, Oka S, Ono Y, Yamamoto C et al. Benefits of mycophenolate mofetil for refractory graftversus-host disease. Rinsho Ketsueki 2007;48:624-631.
37. Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 2006;83:80-85.
38. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56-61.
39. Alousi A, Weisdorf DJ, Logan BR, Bolanos-Meade J, Goldstein SC, Ho VT et al. BMT CTN 0302: a Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft vs Host Disease (aGVHD). Presented at American Society of Hematology Meeting, San Francisco, USA, December 2008.